Uncategorized Archives - Microbiome Times Magazine

Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections

January 20, 2021 Staff Editor

Felix Biotechnology announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for targeted phage therapy YPT-01 in the treatment of chronic P. aeruginosa infections in cystic fibrosis. This double-blind, […]

The Microbiome Biotech Landscape: An Analysis of the Pharmaceutical Pipeline

March 26, 2020 Luis Gosálbez

Introduction The microbiome is one of the hottest areas in biotechnology, as countless studies have linked its composition and activity with human disease1,2, especially in illnesses of poorly understood mechanisms, with high medical unmet needs. […]